Physician profile
Leonard Berkowitz
NPI 1265534564
$1,132.74
in general payments reported to CMS, 2019-2025
15 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.18 · 2021: $39.67 · 2022: $293 · 2023: $283 · 2024: $315 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $550.90 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $96.81 | 2022-2025 | Pifeltro, Delstrigo |
| Gilead Sciences, INC. | $88.95 | 2022-2023 | |
| Eisai INC. | $77.06 | 2024 | |
| Tolmar, INC. | $45.03 | 2025 | Jatenzo |
| Abbvie INC. | $43.37 | 2021-2022 | |
| Melinta Therapeutics, LLC | $38.18 | 2019 | |
| Janssen Biotech, INC. | $35.05 | 2022 | |
| Neurocrine Biosciences, INC. | $26.70 | 2024 | Ingrezza |
| Exact Sciences Corporation | $26.29 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $25.09 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.53 | 2024 | Acthar |
| Vanda Pharmaceuticals INC. | $21.08 | 2025 | Ponvory |
| Vifor Pharma, INC. | $19.93 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.